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Abstract
Heparan sulfates (HSs) have potential therapeutic value as anti-inflammatory and antimetastasis
drugs, in addition to their current use as anticoagulants. Recent advances in chemoenzymatic
synthesis of HS provide a way to conveniently produce homogenous HS with different biological
properties. Crystal structures of sulfotransferases involved in this process are providing atomic
detail of their substrate binding clefts and interactions with their HS substrates. In theory, the
flexibility of this method can be increased by modifying the specificities of the sulfotransferases
based on the structures, thereby producing a new array of products.
Introduction
Heparan sulfate (HS) is an abundant molecule present on the mammalian cell surface and
plays a key role in a wide range of physiological functions, including regulation of
embryonic development and of inflammatory responses [1]. The position and density of the
sulfo groups and iduronic acid (IdoA) units dictate the function of these polysaccharides [2].
The HS sulfotransferases are a class of enzyme that transfer a sulfo group from the sulfo
donor, 3′-phosphoadenosine 5′-phosphosulfate, to the hydroxyl (–OH) and amino (–NH2)
positions of the saccharide residues present in polysaccharides (reviewed in Ref. [3]). Four
different types of HS sulfotransferases have been discovered, including N-deacetylase/N-
sulfotransferases (NDSTs), 2-O-sulfotransferases (2OSTs), 6-O-sulfotransferases (6OSTs),
and 3-O-sulfotransferases (3OSTs), and each subtype has regioselectivity toward a specific
position of the saccharide unit (Supplementary Figure 1). All HS sulfotransferases act on the
polysaccharide backbone with a repeating disaccharide unit of glucuronic acid (GlcA) or
IdoA and glucosamine to form the highly sulfated HS polysaccharide. In the past few
decades, gene knockout experiments in mice and lower organisms have revealed the
physiological significance of HS sulfotransferases [4]. However, the overall mechanism
controlling HS biosynthesis remains enigmatic. Understanding how sulfotransferases
specifically recognize their substrates is advancing our knowledge of this biosynthesis
process.
The availability of crystal structures of HS sulfotransferases, especially those of ternary
complexes containing oligosaccharide substrates, has elevated the understanding of the
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substrate specificities of HS sulfotransferases to a new level. This review aims to summarize
recent advances in HS synthesis with crystallographic analysis, to provide insight into how
the sulfotransferases recognize their saccharide substrates.
Chemoenzymatic synthesis of HS oligosaccharides
A number of approaches including chemical, enzymatic and cell-based methods are
currently being developed for production of HS [5–7,8••,9,10•]. These HS products are
essential to probe structure–function relationships in given biological systems, as well as for
HS-based drug discovery. To date, the inability to access specific structurally defined HS
has severely limited progress in HS-related research. Heparin, a prevalent clinical
anticoagulant drug, is a specialized form of HS that contains a higher sulfation level and
higher IdoA content. Heparin is currently isolated from porcine intestine or bovine lung
through a poorly regulated supply chain. The worldwide distribution of contaminated
heparin in 2007 raised concerns over the safety and reliability of animal-sourced heparins
[11]. A cost-effective, quality-assured method for preparing synthetic heparin is, therefore,
highly desirable. Furthermore, a facile method for preparing heparin enables engineering of
HS/heparin with improved anticoagulant efficacy and reduced side effects, as well as
exploiting heparin or heparin-like molecules for the development of anticancer, anti-
inflammatory and antiviral drugs [12,13•,14,15•]. Although heparin fragments can be
synthesized by a purely chemical method, the synthesis is extremely challenging, especially
for products larger than a hexasaccharide [5]. Recently, a new chemoenzymatic approach
offers a simplified synthetic route for preparing heparin and HS fragments with diversified
sulfation patterns [8••]. Using recombinant glycosyltransferases and HS sulfotransferases,
the saccharide chain can be extended one sugar at a time, followed by controlled sulfation,
to produce the desired homogenous HS. This approach was critical in obtaining a
homogeneous heptasaccharide for cocrystallization with 3OST isoform 1, providing insight
into HS binding for the production of anticoagulant HS (Figure 1) [16•]. Accordingly,
improved knowledge of HS interactions with the biosynthetic enzymes will further enhance
the chemoenzymatic method for preparing HS for research and therapeutic purposes.
Overall fold of HS sulfotransferases
To date, crystal structures exist for the sulfotransferase domains of three of the four HS
sulfotransferases: NDST1 (NST-1), 2OST, and three 3OSTs (isoforms 1, 3, and 5) (Figure
2) [16•,17–21]. Currently, no structural information has been published for 6OST. The
3OSTs share 30% sequence identity with NST-1, while these enzymes share less than 15%
identity to 2OST. Despite low sequence conservation, they have structurally similar folds
and catalytic features. At the heart of these enzymes lies an α/β motif with a core five-
stranded parallel β-sheet. Central to this motif is a strand-loop helix structure (PSB-loop)
involved in binding the 5′-phosphosulfate of the PAPS cofactor, and a conserved α-helix
(α6) that runs across the top of the β-sheet (Figure 2a) [22]. HS sulfotransferases contain a
large hydrophilic cleft oriented perpendicular to the plane of the β-sheet. This cleft properly
positions large, linear polysaccharide substrates for the proposed catalytic SN2 in-line
displacement attack required for sulfo transfer [16•,19]. The catalytic base for 2OST appears
to be a conserved histidine (His142), located at the end of the fourth β-strand of the core β-
sheet (Figure 3a). NST-1 and 3OSTs lack this residue, instead utilizing a glutamate found on
a loop (not present in 2OST) after the last strand of the β-sheet (Figure 3a). Also absent in
2OST is a three-stranded antiparallel β-sheet on the exterior of the central core (Figure 2c).
Unlike the 3OSTs and NST-1, 2OST forms a symmetrical trimer that buries nearly 25% of
the surface area for each molecular unit (Figure 3c) [21]. This arrangement positions all the
N-termini on the same face of the trimer, suggesting its orientation with respect to the Golgi
membrane (Figure 3d). A significant contribution to the trimer formation comes from the C-
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terminal tail that extends away from the core and forms an antiparallel β-sheet arrangement
with the edge of the central β-sheet in the substrate binding cleft of a neighboring molecule
(Figure 3b, red). Supporting the crystallographic analysis, truncation mutants of this tail
have disrupted trimer formation and reduced sulfotransferase activity [21].
N-deacetylase/N-sulfotransferase
Biological relevance
There are four isoforms of NDST in humans [23–25]. NDSTs catalyze the first HS sulfation
event, generating the substrate for subsequent epimerization and sulfation steps (Figure 1
and Supplementary Figure 1). Different expression levels of the isoforms may create varying
degrees of N-sulfation in different tissues [26]. NDST-1 is the predominant isoform in most
tissues while NDST-2 is the major isoform in mast cells that produce heparin [25]. It has
been demonstrated that NDST-1 sulfates HS from the non-reducing end, toward the
reducing end along a chain of -GlcA-GlcNAc-, and terminating sulfation five saccharides
short of a sulfated GlcNS. This creates patches of sulfated and unsulfated regions [27,28].
NDSTs have two separate domains: the N-deacetylase domain and the sulfotransferase
domain (NST). Neither structures of the full length nor N-deacetylase domain of NDST are
currently available.
Oligosaccharide binding
The structure of NST (Figure 2b) lacks bound substrate. However, certain mutations along
the proposed binding cleft can greatly affect activity, suggesting a role in substrate binding
[17,29]. NST-1 contains a six amino acid insertion before the catalytic base not present in
the 3OSTs. This region likely contributes to substrate binding as point mutations in this area
(F640A and E641A) significantly affect activity [29]. Other residues that line the substrate
binding pocket and which appear to contribute to substrate binding are Trp713, His716, and
His720 from conserved helix α6 [29].
2-O-sulfotransferase
Biological relevance
Only a single isoform of 2OST exists in humans and its sequence is highly conserved across
species [30]. 2OST preferentially sulfates IdoA, but is also capable of sulfating GlcA [31].
IdoA2S is critical for FGF binding, dimerization, and mediating downstream signal
transduction pathways [32]. To date, there is no known physiological function for GlcA2S;
however, reports indicate that it has been found in HS from adult human brain and in nuclei
of rat hepatocytes [33,34].
Oligosaccharide binding
Similar to NST-1 (Figure 2b), the structure of 2OST (Figure 2c) lacks bound substrate;
however, some insight into substrate recognition has been derived from site directed
mutagenesis. Alanine mutations of Tyr94, His106, Asp181, Tyr183, Arg189, and/or Lys350
all have a significant effect on activity when using two substrates—one containing only
IdoA and the other containing only GlcA (Figure 3b) [21]. Single mutations of D181A,
Y183A, and K350A result in decreased activity against both Ido-containing and GlcA-
containing substrates suggesting a general role in polysaccharide binding. However, the
single mutants Y94A and H106A show substantial loss of activity for the GlcA substrate
relative to the IdoA substrate, suggesting a role for Tyr94 and His106 in GlcA sulfation.
Alternatively, the mutant R189A virtually eliminates sulfation of IdoA while maintaining
wild-type activity for the GlcUA substrate which supports a role in IdoA binding. The
different ring conformations associated with the two isomers GlcA and IdoA likely places
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key substituents on the saccharide in different positions, ultimately affecting protein
interaction. Future crystal structures of these mutants with different substrates will be
essential for understanding their substrate preferences.
3-O-Sulfotransferases
Biological relevance
In humans, there are seven isoforms of 3OSTs: 3OST-1, 2, 3a, 3b, 4, 5, and 6 [35–37].
These isomers have two established substrate preferences. 3OST-1 preferentially sulfates a
GlcNS±6S with a GlcA residue on its nonreducing end. 3OST-1-like activity produces
anticoagulant HS [38]. The 3-O-sulfation increases the binding affinity of HS to
antithrombin III by almost 20,000 fold [39]. 3OST-3 prefers to sulfate a GlcNS±6S with an
IdoA2S on the nonreducing end. The product from a 3OST-3-like modification functions as
a coreceptor in herpes simplex virus type 1 entry by binding to the glycoprotein D on the
viral surface [36,40]. 3OST-2, 3OST-4, and 3OST-6 appear to have substrate preferences
similar to 3OST-3, while 3OST-5 is more promiscuous and displays activity for both
defined substrates (Supplementary Figure 1) [36–38,41–43].
Oligosaccharide binding
Currently there are two ternary structures of 3OSTs: 3OST-1 with a bound heptasaccharide
(Figures 2d, 4a and c) and 3OST-3 with a bound tetrasaccharide (Figures 2e, 4b and c) [16•,
19]. These complexes provide a wealth of information on substrate specificity differences
between the 3OSTs. Though the two oligosaccharide substrates share a common
trisaccharide motif (GlcNS6S-IdoA2S-GlcNS6S) on their reducing end, the IdoA2S residue
in the trisaccharide sequence displays significant structural differences when bound to
3OST-1 versus 3OST-3 (Figure 4). IdoA residues in HS can be found in either a 2S0 skew
boat or a 1C4 chair conformation [44,45]. In the 3OST-3 structure, the IdoA2S residue of the
trisaccharide is found in the 2S0 conformation, while adopting a 1C4 conformation when
bound to 3OST-1 (Figure 4c). The conformational difference of the IdoA2S, combined with
a kink and rotation in the glycosidic bond to the nonreducing end acceptor GlcNS6S, alters
the positioning of the reducing end. In 3OST-3, the binding of the reducing end to the
protein is mediated via a metal ion (likely sodium) that forms interactions with this IdoA2S
and the terminal GlcNS6S (Figure 4c) [19]. In 3OST-1, the position of the reducing end is
mediated by direct interactions with the protein [19].
It was thought that a conformational difference might exist between the GlcA (H-2 for
3OST-1 substrate) and the ΔUA2S (T-1 for 3OST-3 substrate) that dictates substrate
specificity for each isoform (Figure 4a and b, red bracket). Surprisingly, both residues bind
to the enzymes in similar orientations (Figure 4c). For 3OST-1, the GlcA is found in the 4C1
chair conformation while 3OST-3 binds the ΔUA2S in a 2H1 half-chair that superimposes
well with the GlcA. Despite the similar positioning, the superposition of the GlcA and
ΔUA2S suggests how the sugar identity at this position may influence binding preference.
The GlcA in the 3OST-1 substrate probably cannot be 2-O-sulfated, as the extra sulfo group
would likely be located ~2.8 Å from the carboxylate on the reducing end IdoA2S (H-4),
which places two negatively charged groups in close proximity. For the 3OST-3 substrate,
the 2-O-sulfo group of the ΔUA2S is located farther away (3.2 Å) from the carboxylate on
the IdoA2S (T-3) and within hydrogen bonding distance to Lys259 (Figure 4c). Lys259 may
ameliorate the charge repulsion in this area, a role that is supported by severe loss of
function that results from alanine substitution. This residue is highly conserved in
mammalian 3OST-3s but is not conserved in 3OST-1 [19].
In addition to the residues near the active site, residues located at a remote ‘gate’ influence
the activity and specificity of 3OSTs (Supplementary Figure 2) [20]. Manipulation of these
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residues alters the substrate specificity of 3OSTs. In the 3OST-1 structure, without substrate
present (Supplementary Figure 2A) [18], this gate is narrow (6.7 Å) in comparison to
3OST-3 and 5 (14.2 Å for both, Supplementary Figure 2b and c) [19,20]. It has been
demonstrated that a double mutation of these gate residues in 3OST-5 (S120E/A306H) to
those of 3OST-1, greatly reduces the 3OST-3-like activity while enhancing the 3OST-1 like
activity [20]. A double mutation of these gate residues in 3OST-1(H271G/E88G) to 3OST-3
residues increased the relative amount of 3OST-3 activity versus 3OST-1 like activity,
decreasing substrate selectivity [20]. The structure of 3OST-1 with heptasaccharide bound
suggests that the nonreducing end of the HS can extend into the gate (Supplementary Figure
2d and e) [16•]. It should be noted that upon binding of the substrate, gate residue His271 in
3OST-1 adopts a different rotamer to accommodate the substrate, effectively ‘opening’ the
gate. Glu88 becomes disordered in the presence of the substrate, and the apparent motility of
these residues leads to speculation as to possible relevance for substrate specificity. Alanine
substitution of R268 (located just past the gate) contributes to 3OST-1 activity, emphasizing
the importance of this region to 3OST-1 for substrate binding (Supplementary Figure 2d and
e). Interestingly, mutations of 3OST-3 gate residues to those of 3OST-1, significantly
reduces sulfotransferase activity without affecting substrate specificity. It is clear from these
studies that the interactions with the substrate across the entire length of the cleft contribute
to binding as well as specificity of the 3OST isoform [16•,20].
Conclusion
The evolving crystal structures of HS sulfotransferases are yielding detailed information on
substrate binding, and subsequently providing the blueprint for engineering the
sulfotransferases through mutagenesis. These mutants allow for more precisely controlled
synthesis of functionally distinct HS. Chemoenzymatic synthesis can supply specific
oligosaccharide substrates for more informative crystal structures, revealing the key
interactions between proteins and carbohydrates at atomic resolution. Our experience
demonstrates that the structural studies and synthesis are intimately linked. The crystal
structure of 3OST-1 represents the first example of the power of this synergistic approach.
Future efforts will undoubtedly expand the capability of the chemoenzymatic synthesis for
production of HS therapeutics as well as significantly contribute to research in HS-related
and heparin-related glycomics.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Chemoenzymatic synthetic scheme for the synthesis of HS heptasaccharide (a substrate for
3OST-1 [16•]). The starting material is a disaccharide (GlcA-AnMan, where AnMan
represents 2,5-anhydromannitol). The synthesis includes nine steps, involving the backbone
elongation as well as sulfation and epimerization. Five elongation steps convert a
disaccharide to a heptasaccharide (steps a–c), which is achieved by N-acetylglucosaminyl
transferase from E. coli K5 strain (for N-trifluoroacetyl glucosamine (GlcNTFA, step a) and
GlcNAc transfer, step c) and heparosan synthase 2 of Pasteurella multocida (for GlcA
transfer, step b). The conversion of a GlcNTFA to a GlcNS residue is completed in two
steps, including detrifluoroacetylation under alkaline conditions (step d) and N-sulfation by
NST (step e). The conversion of a GlcA to an IdoA2S reside is carried out by both C5-
epimerase and 2OST (step f). The 6-O-sulfation (step g) is completed by the mixture of
6OST-1 and 6OST-3.
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Crystal structures of HS sulfotransferases. (a) Core secondary structural elements of the HS
sulfotransferases with bound cofactor product PAP (pink). These enzymes display an α/β
motif wherein a central five-stranded parallel β-sheet (blue) is flanked by α-helices. The
highly conserved strand-loop-helix (green) which contains the PSB-loop, is critical for
binding of the universal sulfate donor PAPS. The α6 helix (orange) is a major structural
component of the substrate binding cleft. (b) Binary complex of the sulfotransferase domain
of murine NDST1 with bound PAP cofactor (PDB ID: 1NST). (c) Binary complex of
chicken 2OST with bound PAP cofactor (PDB ID: 3F5F). The C-terminal tail is colored red.
(d) Ternary complex of murine 3OST-1 with PAP and bound chemoenzymatically
synthesized heptasaccharide substrate (cyan) (PDB ID: 3UAN). (e) Ternary complex of
human 3OST-3 with PAP and a tetrasaccharide substrate (purple) prepared from hydrolase
treated heparin (PDB ID: 1T8U). (f) Binary complex of human 3OST-5 with bound PAP
cofactor (PDB ID: 3BD9). The small three-stranded antiparallel β-sheet present in NDST1
and the 3OSTs is marked by a red bracket. The PAP cofactor is drawn in stick (pink). These
figures were generated in PyMOL [46].
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Key structural characteristics of 2OST. (a) Active site architecture of 2OST, as compared to
3OST-1. Chicken 2OST (blue, PDB ID: 3F5F) was superimposed with murine 3OST-1
(gold, PDB ID: 3UAN), using the PSB-loop as a reference. The residues acting as a catalytic
base for each molecule (His142 in 2OST, green; Glu90 in 3OST-1, orange) are shown in
stick. Both conformations of His142 present in the crystal structure are shown. The location
of the C-terminal tail from a neighboring 2OST monomer in the trimer is displayed in red. A
purple asterisk has been placed at the position the acceptor hydroxyl of the heptasaccharide
bound to 3OST-1. (b) 2OST residues that were determined by structurally guided
mutagenesis to play roles in substrate binding and/or specificity. The proposed catalytic
base, His142 (green) displays the estimated location of sulfo transfer. Alanine substitution of
Asp181, Tyr183, and/or Lys350 (from a neighboring monomer, red) reduces
sulfotransferase activity as a result of impaired substrate binding. Mutations of Tyr94,
His106, and Arg189 alter specificity. (c) Trimer of 2OST (white, slate blue, navy blue) with
the C-terminal tails shown in red. (d) Proximal grouping of the N-termini from each of the
three monomer units suggests the orientation of the trimeric 2OST with respect to the Golgi
membrane.
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Comparison of substrate binding by the 3OSTs. (a) The chemoenzymatically synthesized
heptasaccharide substrate crystallized with 3OST-1 (PDB ID: 3UAN). (b) The heparin
hydrolase produced tetrasaccharide crystallized with 3OST-3 (PDB ID: 1T8U). Reduction of
the uronic acid residue (T-1) is a result of the hydrolase reaction. The saccharide unit
determining the substrate specificity for either 3OST-1 (GlcA) or 3OST-3 (IdoA2S) is
bracketed in red. The reducing end trisaccharide motif of identical sequence between the
two is boxed in black. (c) Conformational differences for oligosaccharide substrates bound
to 3OST-1 (cyan) versus 3OST-3 (purple). Superposition of these two substrates provides a
structural basis for the preference of a 2-O-sulfated saccharide unit on the nonreducing side
of the acceptor GlcNS6S (residue H-4 for 3OST-1 or T-3 for 3OST-3). Residues from
3OST-3 that affect substrate specificity are drawn in gray stick. While 3OST-1 interacts
directly with its substrate, 3OST-3 utilizes a metal ion (likely sodium, green) to mediate
contacts with the reducing end of its substrate.
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